RENB Research | Milton Maxwell

RENB

Lunai Bioworks Inc.

1.4200

+0.0000+0%

Nov 25, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

33.82M

P/E (TTM)

Basic EPS (TTM)

-10.80

Dividend Yield

Recent Filings

8-K

Temporary employee furlough

3/5/26Mar 5, 2026

Lunai Bioworks implemented a temporary employee furlough in the US and Canada on February 27, 2026, to preserve liquidity amid financing pursuits. CEO and CFO voluntarily deferred salaries. Furlough duration hinges on securing capital; some operational staff already recalled. Leadership steps buy time.

8-K

Nasdaq delisting hearing granted

2/23/26Feb 23, 2026

Lunai Bioworks faces Nasdaq delisting after Staff determination on February 6, 2026, but won a hearing stay. Panel hearing set for March 26. Delisting paused pending decision. No assurance of continued listing.

10-Q

Q2 FY2026 results

2/17/26Feb 17, 2026

Lunai Bioworks slashed operating expenses 60% y/y to $1.8M in Q2 FY2026 ended December 31, 2025, driving operating loss to $1.8M from $4.5M, while six-month ops loss of $5.1M excluded $47.6M goodwill hit last year. Net loss narrowed to $1.8M ($0.08/share) versus $7.3M ($0.45/share), with YTD flipping to $1.0M profit ($0.04/share, 23.1M diluted shares) on $12.0M gain from GediCube bankruptcy deconsolidation, offset by $6.3M debt extinguishment loss. Cash climbed to $492K (up from $93K at June 30), but ops burned $2.4M with no FCF disclosed; liabilities dropped to $20.2M, working capital deficit $19.5M. BioSymetrics acquisition added $6.0M goodwill. Cash stays perilously thin.

8-K

Nasdaq delisting notice issued

2/12/26Feb 12, 2026

Lunai Bioworks received Nasdaq notice on February 6, 2026, for delisting due to bid price below $1.00 for 30 days ending February 5, post its September 30, 2025, 1-for-10 reverse split. No compliance period granted. Company appealed; hearing stays suspension. Appeal may fail.

8-K

ATM equity offering launched

12/3/25Dec 3, 2025

Lunai Bioworks entered an at-the-market sales agreement on December 2, 2025, with Dawson James Securities to offer up to $11.70 million in common stock via Nasdaq. The agent earns 3.0% commission on gross proceeds. Sales remain optional; either party can terminate on notice. Forward-looking statements highlight commercialization risks.

About

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

CEO

Mr. David H. Weinstein

IPO

2/2/2015

Website

https://renovarogroup.com

Sector

Healthcare

Industry

Biotechnology